$IDYA News

Wedbush Reiterates Outperform on IDEAYA Biosciences, Maintains $58 Price Target

IDEAYA Biosciences And Servier Presented Complete Data From Primary Analysis Of Phase 2/3 OptimUM-02 Trial For Negative Metastatic Uveal Melanoma At ASCO Annual Meeting

IDEAYA Biosciences, Inc. (IDYA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Mizuho Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $50

IDEAYA Biosciences Files Prospectus For Mixed Shelf Offering; Size Not Disclosed

IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

IDEAYA Biosciences Q1 EPS $(1.11) Misses $(0.98) Estimate, Sales $6.560M Beat $5.008M Estimate

Is IDEAYA Biosciences, Inc. (IDYA) A Good Stock To Buy Now?

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program

IDEAYA Biosciences, Inc. (IDYA) PT Increased as Wedbush Highlights Positive OptimUM-02 Trial Readout

IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma

IDEAYA Biosciences Reveals Late-Breaking Abstract Oral Presentation At ASCO 2026 To Provide Complete Data from Phase 2/3 Registrational Trial Of Darovasertib In Combination With Crizotinib In 1L HLA*A2-Negative Metastatic Uveal Melanoma

Goldman Sachs Maintains Neutral on IDEAYA Biosciences, Raises Price Target to $35

Wells Fargo Maintains Overweight on IDEAYA Biosciences, Raises Price Target to $48

RBC Capital Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $53

Wedbush Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $58

Guggenheim Maintains Buy on IDEAYA Biosciences, Raises Price Target to $54

IDEAYA Biosciences Unveils OptimUM-02 Data: Darovasertib/Crizotinib Doubles PFS in Uveal Melanoma

Ideaya Biosciences Surges On Promising Results For Hard-To-Treat Melanoma